David Hoang
Stock Analyst at Deutsche Bank
(1.86)
# 2,964
Out of 4,784 analysts
38
Total ratings
37.93%
Success rate
-8.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $33.21 | +56.58% | 2 | Mar 27, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $124 → $99 | $70.41 | +40.61% | 6 | Mar 19, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $34.26 | +95.56% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $38.66 | +187.12% | 1 | Feb 11, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $55 | $33.19 | +65.71% | 2 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $14.78 | +109.74% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $27.65 | +135.08% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $118.53 | +48.49% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $8.01 | +49.81% | 1 | Feb 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $17.07 | +34.74% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $113.16 | +39.63% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.19 | +488.24% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $8 | $8.28 | -3.38% | 1 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.32 | +270.37% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.65 | +338.36% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $268.46 | -18.05% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $13.82 | +478.87% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $1.17 | +156.41% | 1 | Dec 7, 2022 |
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $33.21
Upside: +56.58%
Sarepta Therapeutics
Mar 19, 2025
Maintains: Hold
Price Target: $124 → $99
Current: $70.41
Upside: +40.61%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $34.26
Upside: +95.56%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $38.66
Upside: +187.12%
Harmony Biosciences Holdings
Feb 11, 2025
Initiates: Buy
Price Target: $55
Current: $33.19
Upside: +65.71%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $14.78
Upside: +109.74%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $27.65
Upside: +135.08%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $118.53
Upside: +48.49%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $8.01
Upside: +49.81%
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $17.07
Upside: +34.74%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $113.16
Upside: +39.63%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.19
Upside: +488.24%
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $8.28
Upside: -3.38%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $4.32
Upside: +270.37%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.65
Upside: +338.36%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $268.46
Upside: -18.05%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $13.82
Upside: +478.87%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $1.17
Upside: +156.41%